Estrogen News and Research

Latest Estrogen News and Research

Bisphenol A (BPA) containing baby bottles to be phased out

Federal Parliamentary Secretary for Health Mark Butler has announced that following public concern and a safety review ordered by US health regulators, the phase out will begin from today. He also revealed that according to Food Standards Australia New Zealand intake levels are very low and do not pose a risk to babies' health.

1 Jul 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

APP to market Anastrozole 1 mg tablets in U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited.

29 Jun 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

EVISTA improves bone quality as measured by HRpQCT: IIT

Interim data from a prospective Investigator Initiated Trial presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the treatment and prevention of osteoporosis in postmenopausal women, improves bone quality as measured by the high-resolution peripheral quantitative computed tomography.

28 Jun 2010

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Researchers at UT Southwestern Medical Center have pinpointed a set of biological mechanisms through which estrogen confers its beneficial effects on the cardiovascular system, independent of the hormone's actions on cancer. Their investigation suggests that drugs targeting a specific subpopulation of estrogen receptors found outside the cell nucleus might activate the cardiovascular benefits of estrogen without increasing cancer risk.

24 Jun 2010

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

The Endocrine Society presented its Scientific Statement on menopausal hormone therapy Monday in San Diego, Calif. at ENDO 2010: The 92nd Annual Meeting & Expo.

23 Jun 2010

Oral micronized progesterone effective for women with symptomatic hot flashes

Postmenopausal women who experience bothersome hot flashes or night sweats may have an alternative treatment to estrogen. According to a new study, oral micronized progesterone relieves those symptoms. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Women with PCOS may be more vulnerable to BPA exposure: Study

Women with the polycystic ovary syndrome, the most common hormone imbalance in women of reproductive age, may be more vulnerable to exposure to the chemical bisphenol A, found in many plastic household items, according to a new study. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Exposure to BPA in early life may affect testis function into adulthood

Exposure to environmental levels of the industrial chemical bisphenol A, or BPA, in the womb and early life may cause long-lasting harm to testicular function, according to a new study conducted in animals. The results are being presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Ostarine increases muscle mass and strength in postmenopausal women: Study

GTx, Inc. announced that Ostarine (GTx-024, formerly MK-2866) increased lean body mass and leg press strength in a head to head study evaluating Ostarine and another selective androgen receptor modulator, MK-3984, in postmenopausal women. The data were presented yesterday at the 2010 Annual Meeting of the Endocrine Society. GTx is developing its lead SARM, Ostarine, for the treatment of cancer induced muscle wasting (cancer cachexia).

21 Jun 2010

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Within the first week after giving birth, up to 70 percent of all women experience symptoms of the baby blues. While most women recover quickly, up to 13 percent of all new mothers suffer from symptoms of a clinical-level postpartum depression. Postpartum depression is defined as a major depressive episode starting within 4 weeks after delivery and is a significant public health problem. Postpartum blues represents a major risk factor for developing postpartum depression and severe postpartum blues symptoms can be viewed as a prodromal stage for postpartum depression.

17 Jun 2010

Smokeless tobacco affects normal function of CYP-450 family of enzymes: Report

Far from having adverse effects limited to the mouth, smokeless tobacco affects the normal function of a key family of enzymes found in almost every organ in the body, according to the first report on the topic in ACS' monthly journal Chemical Research in Toxicology. The enzymes play important roles in production of hormones, including the sex hormones estrogen and testosterone; production of cholesterol and vitamin D; and help the body breakdown prescription drugs and potentially toxic substances.

17 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

CT angiography not necessary in patients suspected with pulmonary embolism

A new study suggests that computed tomography (CT) angiography might be unnecessary in many patients suspected of having pulmonary embolism (PE), based on the results of risk assessment analysis. PE risk assessment could help reduce radiation exposure and costs associated with CT angiography. The results of the study appear in the online edition and August print issue of the journal Radiology.

15 Jun 2010

Agile Therapeutics completes $45 million Series B Preferred Stock financing round

Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women's healthcare products, today announced that it completed a $45 million Series B Preferred Stock financing. The financing round was co-led by Investor Growth Capital and Care Capital, with strong participation from ProQuest Investments. Kaiser Permanente Ventures and Novitas Capital also joined the financing round. Investor Growth Capital, Care Capital, and Kaiser Permanente Ventures are new investors to Agile.

14 Jun 2010

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

The College of American Pathologists and the American Society of Clinical Oncology today issued a joint guideline aimed at improving the accuracy of immunohistochemistry testing for the expression status of estrogen and progesterone receptors in breast cancer. The two groups conducted a systematic review of medical research literature in partnership with Cancer Care Ontario to develop the recommendations.

14 Jun 2010

Study results of genes regulated by ERB published in Journal of Biological Chemistry

Bionovo Inc. today announced the publication of results from a study demonstrating the three distinct classes of genes regulated by estrogen receptor beta. The results are published in the Journal of Biological Chemistry. This is an important discovery for future development of selective drugs regulating this pathway.

11 Jun 2010

GTx reports positive results from toremifene Phase III clinical trial

GTx, Inc. announced today that in the Phase III clinical trial evaluating toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects in men with prostate cancer on androgen deprivation therapy (ADT), toremifene treatment demonstrated an improved benefit/risk ratio in men less than 80 years of age. The data were presented yesterday at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

8 Jun 2010

Estrogen News and Research

Latest Estrogen News and Research

Bisphenol A (BPA) containing baby bottles to be phased out

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

APP to market Anastrozole 1 mg tablets in U.S.

Merck challenges New York jury decision in federal FOSAMAX retrial

EVISTA improves bone quality as measured by HRpQCT: IIT

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

Oral micronized progesterone effective for women with symptomatic hot flashes

Women with PCOS may be more vulnerable to BPA exposure: Study

Exposure to BPA in early life may affect testis function into adulthood

Ostarine increases muscle mass and strength in postmenopausal women: Study

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Smokeless tobacco affects normal function of CYP-450 family of enzymes: Report

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

CT angiography not necessary in patients suspected with pulmonary embolism

Agile Therapeutics completes $45 million Series B Preferred Stock financing round

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

Study results of genes regulated by ERB published in Journal of Biological Chemistry

GTx reports positive results from toremifene Phase III clinical trial

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Estrogen News and Research

Latest Estrogen News and Research

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in